- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00775567
Effect of Fructose on Colonic Microflora (MEF)
Colonic Microbial and Clinical Adaptation to Large Doses of Fructose
Fructose is the principal carbohydrate in fruits and is added to many food products. This 6 carbon sugar is associated with a number of ill effects, like promotion of high triglycerides,precipitation of gout in men,possible depression in women and symptoms of intolerance in a non ethnic dose dependent fashion.However, high fruit and vegetable intake is associated with some epidemiologic evidence in prevention of some cancers like stomach and colorectum.The principal protectors in these products are thought to be antioxidants and other protective chemicals like polyphenols.In addition long chain polymers of fructose:inulin are thought to help protect against cancer through prebiotic effects. In fact poly-fructose molecules are used as prebiotic food supplements and are promoted as aids for a healthy intestine with "balanced microflora".
Polyfructose prebiotics induce some gastrointestinal symptoms of cramps gas bloating and sometimes diarrhea.To date repeated consumption of these polyfructose molecules have not been shown to induce colonic adaptation. Nor is there evidence that fructose intolerant people "adapt " to prolonged ingestion.
These findings are in contrast to findings with lactose intolerance where prolonged ingestion leads to both symptomatic and physiological adaptation.In this interventional study we evaluate whether fructose intolerant people can adapt to moderate dose daily fructose ingestion.The desired outcome is symptomatic, physiological and colonic microfloral adaptation. A failure to detect an increase in bifidobacteria on retesting may suggest that in humans like in some other mammals GLUT5 fructose transport could be induced.
Study Overview
Detailed Description
The concept of Colonic Adaptation(CA) to regular carbohydrates has been linked mainly to lactose disaccharide(galactose,glucose) and lactulose(galactose, fructose), a manufactured derivative of lactose. CA is achieved in both cases by short term regular consumption of the targeted sugar which is not digested by the host. The clinical definition of CA includes a measured change in breath hydrogen, reduction of clinical symptoms (Bloat, gas, cramps and at times diarrhea) and an associated increase of bacterial lactase(β-galactosidase. The putative mechanism is through bacterial action which results in enhanced metabolism or expanded bacterial population of specific genus and species of bacteria. The act of CA may incur health benefits through physicochemical changes and especially promotion of health promoting bacteria.
Maldigestion of fructose occurs in the population probably in a dose dependent fashion. The sugar content overwhelms the principal GLUT5 intestinal carrier. In the presence of glucose this non energy dependent system works better(11). In a previous publication we found that the pre test graded ingestion of fructose had no impact on test results. These results were dramatically different from that found for pretest lactose ingestion. The investigators interpreted the results from the fructose study as being consistent with a failure to show CA to regular fructose consumption.
More recently Rao et al however, showed that there may be a threshold level of intake beyond which fructose maldigestion may rapidly increase. This value was thought to be 15-20g. In the case of lactose this was 10g(15). Since in both our studies we used the same dose response analysis(<10,11-19, and >20g/d), it is possible that fructose consuming individuals might not have spilt adequate quantities of fructose into the colon to properly induce and maintain CA. Moreover, there is to our knowledge no information on a possible prebiotic effect of the monosaccharide fructose. Since polymers of fructose are very good prebiotics it may be of interest to determine whether this sugar is capable of prebiotic function in its own right.
The investigators propose to carry out a short term study on 20-30 healthy participants to determine whether a 2 week period of fructose consumption alters clinical CA and intestinal microflora.
Study Outline After an overnight fast, except for water(ad libitum), participants present themselves to the GI lab around 9 am. A 50 gm fructose solution (this dose is associated with a 65% chance of maldigestion(14))will be administered. Breath hydrogen and symptoms will be recorded for 4.5 Hrs at ½ hr intervals. Participants will be asked to fill out a short 3 day diet recall questionnaire targeting fructose ingestion.
Participants will be asked to consume 30g fructose in 150ml of water (lemon juice may be added) twice a day for 14 days.They will then return for a repeat50 g fructose challenge. A small stool sample will be asked from participants at each test period.Another similar group will undergo the same tests but without taking intervening fructose.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- SMBD Jewish General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy participants
Exclusion Criteria:
- Antibiotics 90 days pre entry
- Use of gastrointestinal motility drugs eg loperamide, metoclopramide significant fiber supplements
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: No Intervention
|
|
ACTIVE_COMPARATOR: 1
30g fructose dissolved in water twice a day
|
30g in 250ml water twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Statistically significant reduction in total sum breath hydrogen upon a 50g fructose challenge test.
Time Frame: intervention for 2 weeks per participant
|
intervention for 2 weeks per participant
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
A log 1 change in fecal bifidobacteria or lactobacilli species.
Time Frame: stools retested 2 weeks apart
|
stools retested 2 weeks apart
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andrew Szilagyi, MD, SMBD Jewish General Hospital, McGill university School of Medicine
Publications and helpful links
General Publications
- Szilagyi A, Malolepszy P, Yesovitch S, Vinokuroff C, Nathwani U, Cohen A, Xue X. Fructose malabsorption may be gender dependent and fails to show compensation by colonic adaptation. Dig Dis Sci. 2007 Nov;52(11):2999-3004. doi: 10.1007/s10620-006-9652-9. Epub 2007 Mar 15.
- Rao SS, Attaluri A, Anderson L, Stumbo P. Ability of the normal human small intestine to absorb fructose: evaluation by breath testing. Clin Gastroenterol Hepatol. 2007 Aug;5(8):959-63. doi: 10.1016/j.cgh.2007.04.008. Epub 2007 Jul 10.
- Szilagyi A, Malolepszy P, Yesovitch S, Nathwani U, Vinokuroff C, Cohen A, Xue X. Inverse dose effect of pretest dietary lactose intake on breath hydrogen results and symptoms in lactase nonpersistent subjects. Dig Dis Sci. 2005 Nov;50(11):2178-82. doi: 10.1007/s10620-005-3028-4.
- Briet F, Achour L, Flourie B, Beaugerie L, Pellier P, Franchisseur C, Bornet F, Rambaud JC. Symptomatic response to varying levels of fructo-oligosaccharides consumed occasionally or regularly. Eur J Clin Nutr. 1995 Jul;49(7):501-7.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 07111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Fructose powder
-
Maastricht University Medical CenterActive, not recruiting
-
University of LausanneCompleted
-
Rockefeller UniversityThe Rogosin InstituteCompletedCardiovascular Disease | Diabetes | Elevated TriglyceridesUnited States
-
John SievenpiperCanadian Diabetes Association; The Physicians' Services Incorporated Foundation and other collaboratorsUnknownObesity | Overweight | Body Weight | Adiposity | Obesity, AbdominalCanada
-
University of TorontoCanadian Institutes of Health Research (CIHR); Canadian Diabetes Association; The Physicians' Services Incorporated FoundationUnknownCardiovascular Diseases | Stroke | Hypertension | Diabetes Mellitus, Type 2 | Gout | Metabolic Syndrome XCanada
-
Instituto Nacional de Cardiologia Ignacio ChavezCompletedMetabolic Syndrome | Overweight and Obesity | HyperuricemiaMexico
-
Touro University, CaliforniaRecruitingInsulin Resistance | Insulin Sensitivity | Pre DiabetesUnited States
-
University of CalgaryCompletedChronic Kidney DiseaseCanada
-
University of LausanneUniversity of BernCompletedMetabolic SyndromeSwitzerland
-
University of MilanFondazione Salvatore MaugeriCompletedHyperinflation | COPD | Right Cardiac FailureItaly